Evogene Ltd. has reported its Q3 2025 financial results, revealing a company in the midst of a strategic transformation aimed at leveraging artificial intelligence (AI) technology across both the pharmaceutical and agricultural sectors. While the company faced revenue declines during the period, it simultaneously achieved significant cost reductions and asset sales that have improved its overall financial performance and fuelled cautious optimism about its future prospects.
Central to Evogene’s recent progress has been a successful effort to streamline operations and reduce expenditures. Operating expenses for Q3 2025 fell sharply to approximately $2.9 million, down from $6.6 million in the same period last year. This cutback formed a crucial part of a broader organisational realignment and cost-reduction plan initiated by the company. As a result, total operating loss for the first nine months of 2025 improved significantly to about $8.8 million, compared to a loss of $15.3 million during the comparable period in 2024.
Generating immediate financial benefit, Evogene completed the sale of several assets, notably Lavie Bio’s technology and its MicroBoost AI for agricultural tech engine to Israel Chemicals Ltd. (ICL), which produced income of roughly $7.9 million during Q3. These sales not only bolstered the company’s financials but also reflect a strategic reorientation toward its core competencies, particularly in computational chemistry and generative design of small molecules for pharmaceutical and agricultural applications.
This shift aligns with Evogene’s goal of cementing its position in AI-driven drug and agrochemical discovery, an area underscored by its collaborations with major industry players. Partnerships with Bayer and Corteva through its subsidiary AgPlenus focus on developing new herbicides with novel modes of action, demonstrating Evogene’s ongoing commitment to innovation in the agriculture sector. Furthermore, a collaboration with Google Cloud aims to enhance its ChemPass AI platform, using advanced multiparameter optimisation to accelerate development efforts in both pharmaceuticals and agrochemicals.
Despite these strides, revenue figures illustrate continuing challenges. The company recorded revenues of approximately $3.5 million for the first nine months of 2025, down from $4 million in the prior year. This decline has been primarily attributed to lower revenues derived from AgPlenus’ activities and a drop in seed sales linked to Casterra, which saw quarterly revenues fall from about $1.7 million to $300,000 year-on-year. Research and development expenses also contracted significantly to around $5.9 million in the first nine months of 2025, compared to $9.8 million in the previous year, signalling a sharper focus on cost efficiency.
Evogene also posted a net income of roughly $5.2 million in Q3 2025, a striking reversal from a net loss of $8.2 million in the same quarter last year. This improvement was largely driven by the income from discontinued operations related to asset sales, alongside lower operating expenses and increased financial income. By the end of the third quarter, the company held approximately $16 million in cash and short-term bank deposits, underscoring strengthened liquidity from its recent transactions.
Looking back to 2024, Evogene had already embarked on its strategic journey, evidenced by a 30% reduction in headcount, a 20% cost reduction in research and development expenses, and a notable increase in annual revenues driven by its AgPlenus-Bayer collaboration and Casterra’s seed sales. Despite posting an operating loss of $22.2 million for 2024, the company demonstrated improved cash management and set the stage for its transition towards AI-powered drug discovery.
In summary, Evogene’s Q3 2025 financial results highlight a company balancing significant operational and financial challenges with deliberate strategic shifts and promising collaborations. The successful reduction in operating expenses, asset monetisation, and strengthened partnerships with industry leaders like Bayer, Corteva, and Google signal a cautiously optimistic outlook. The company’s renewed focus on computational chemistry and AI-driven innovation positions it well to capitalise on emerging opportunities in pharmaceuticals and agriculture, aiming for sustainable growth amid a competitive landscape.
📌 Reference Map:
- [1] (The Globe and Mail) - Paragraphs 1, 2, 3, 4, 5, 6, 7
- [2] (TipRanks) - Paragraphs 1, 5, 6
- [3] (Evogene Press Release) - Paragraphs 2, 3, 4
- [4] (Nasdaq) - Paragraphs 2, 4
- [5] (TipRanks) - Paragraphs 1, 5
- [6] (TipRanks) - Paragraphs 1, 5, 6
- [7] (Stock Titan) - Paragraph 7
Source: Noah Wire Services